{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:51:29Z","timestamp":1784242289402,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of an acute coronary syndrome (ACS) in a patient with existing atrial fibrillation (AF) often presents a management dilemma both in the acute phase and post-ACS, since the majority of AF patients will already be receiving oral anticoagulation (OAC) for stroke prevention and will require further antithrombotic treatment to reduce the risk of in-stent thrombosis or recurrent cardiac events. Current practice recommendations are based largely on consensus option as there is limited evidence from randomized controlled trials. Prior to the launch of the new European Heart Rhythm Association (EHRA) consensus document, a survey was undertaken to examine current clinical management of these patients across centres in Europe. Forty-seven centres submitted valid responses, with the majority (70.2%) being university hospitals. This EHRA survey demonstrated overall the management of ACS in AF patients is consistent with the available guidance. Most centres would use triple therapy for a short duration (4\u2009weeks) and predominantly utilize a strategy of OAC (vitamin K antagonist, VKA or non-vitamin K antagonist oral anticoagulant, NOAC) plus aspirin and clopidogrel, followed by dual therapy [(N)OAC plus clopidogrel] until 12 months post-percutaneous coronary intervention, followed by (N)OAC monotherapy indefinitely. Where NOAC was used in combination with antiplatelet(s), the lower dose of the respective NOAC was preferred, in accordance with current recommendations.<\/jats:p>","DOI":"10.1093\/europace\/euz033","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T04:23:34Z","timestamp":1550463814000},"page":"1116-1125","source":"Crossref","is-referenced-by-count":10,"title":["Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey"],"prefix":"10.1093","volume":"21","author":[{"given":"Deirdre A","family":"Lane","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Dagres","sequence":"additional","affiliation":[{"name":"Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[{"name":"Cardiology Department, Colentina University Hospital, University of Medicine \u2018Carol Davila\u2019, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda Seara","sequence":"additional","affiliation":[{"name":"Cardiology Department, Clinical University Hospital of Santiago de Compostela, CIBER Cardiovascular, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Iliodromitis","sequence":"additional","affiliation":[{"name":"Electrophysiology Section, Department of Cardiology, OLV Cardiovascular Center, Aalst, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Lenarczyk","sequence":"additional","affiliation":[{"name":"First Department of Cardiology and Angiology, Silesian Centre for Heart Disease, Curie-Sklodowskiej Str 9, Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Mansourati","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Brest and EA, University of Western Brittany, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBERCV, University of Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scherr","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S","family":"Potpara","sequence":"additional","affiliation":[{"name":"School of Medicine, Belgrade University; Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"2019071004555732900_euz033-B1","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1055\/s-0038-1676074","article-title":"Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision","volume":"118","author":"Proietti","year":"2018","journal-title":"Thromb Haemost"},{"key":"2019071004555732900_euz033-B2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"2019071004555732900_euz033-B3","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"2019071004555732900_euz033-B4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"2019071004555732900_euz033-B5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2019071004555732900_euz033-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2019071004555732900_euz033-B7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"20","author":"Steffel","year":"2018","journal-title":"Europace"},{"key":"2019071004555732900_euz033-B8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2019071004555732900_euz033-B9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2019071004555732900_euz033-B10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/europace\/euu008","article-title":". Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey","volume":"16","author":"Potpara","year":"2014","journal-title":"Europace"},{"key":"2019071004555732900_euz033-B11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1160\/TH16-12-0963","article-title":"Antithrombotic therapy for acute coronary syndrome: past, present and future","volume":"117","author":"Sibbing","year":"2017","journal-title":"Thromb Haemost"},{"key":"2019071004555732900_euz033-B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2019071004555732900_euz033-B13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2019071004555732900_euz033-B14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.pcad.2018.01.008","article-title":"Triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"60","author":"Kerneis","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"2019071004555732900_euz033-B15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12471-018-1120-6","article-title":"Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!","volume":"26","author":"Jacobs","year":"2018","journal-title":"Neth Heart J"},{"key":"2019071004555732900_euz033-B16","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2019071004555732900_euz033-B17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":". Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2019071004555732900_euz033-B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","article-title":"An open-label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"key":"2019071004555732900_euz033-B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J"},{"key":"2019071004555732900_euz033-B20","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/21\/7\/1116\/28918077\/euz033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T08:57:24Z","timestamp":1562749044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/21\/7\/1116\/5381110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,14]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euz033","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,14]]}}}